Can centralized procurement force Chinese pharmaceutical enterprises to accelerate the completion of transformation and innovation?

[pharmaceutical network industry trends] in recent years, the reform of drug procurement mechanism has been accelerating In May 2018, after the official establishment of the National Medical Security Bureau, intensive research was conducted on the medical reform policies in many areas In particular, on September 1, 2019, Shanghai Sunshine pharmaceutical purchase network released the document of centralized drug purchase in the alliance region, which clearly carried out the centralized and volume purchase of drugs in the cross regional alliance, and then expanded the first batch of national drugs "centralized purchase" to the whole country At present, compared with the same variety to low purchase price in 2018 in the expanded area, the average decline rate of 25 selected drugs is 59% It has become a major trend of the industry to guide the drug price reduction in the mode of volume purchase At present, with the continuous promotion of "4 + 7" and other policies, some pharmaceutical enterprises have begun to adjust the product layout of the company to adapt to the market development trend Previously, Hengrui pharmaceutical said it had stopped a number of generic drug development projects based on the measurement of input and output The industry insiders believe that with the nationwide expansion of volume procurement, generic drugs will enter the era of low profit in the future, and generic drugs and innovative drugs with high technical barriers will become the research and development direction of pharmaceutical enterprises From the overall situation of the industry, it seems that centralized mining is forcing Chinese pharmaceutical enterprises to accelerate transformation and innovation Is that really the case? Industry insiders said that, although it has played a certain role in the transformation and innovation of Chinese pharmaceutical enterprises, it is not absolute It makes it clear that pharmaceutical companies have more prospects for developing innovative drugs, but on the contrary, centralized procurement is to make the profit space of generic drugs smaller and the market competition more fierce For China's national conditions, it is to delay the process of the original accumulation of small and medium-sized pharmaceutical enterprises and start-ups From then on, if drug companies want to develop, they will mainly rely on the financial market In other words, in the future, the stronger the strong, the weaker will be eliminated In fact, innovative drugs are more promising, which is the consensus and development trend of the current industry However, it should be clear that not all pharmaceutical companies can transform and innovate rapidly, which does not mean that the innovative medicine track is a smooth road At present, there are a large number of small generic pharmaceutical enterprises in the industry, too much convergence of drug research and development, waste of human, material and financial resources and other issues, which are worthy of attention In addition, in the process of transferring from generic drugs to innovative drugs, pharmaceutical companies are facing changes in the entire management and control system and organizational structure Whether the talents and processes are fully prepared or not, the enterprise should not only have a good top-level design and make continuous efforts in the right direction, but also need the internal skill of the enterprise and its own perfect system Generally speaking, the main focus of the current transformation of Chinese pharmaceutical enterprises should be three aspects: technical barriers, patent portfolio and financing capacity, and the three strong ones are Yu Qiang The transformation of Chinese pharmaceutical enterprises does not need to pay too much attention to centralized procurement Gathering is more like a spur The way forward for Chinese pharmaceutical companies needs to see the overall situation of the industrial chain from a global perspective and work hard from three aspects First of all, it is the key to improve the level of cognition of environment, oneself and trend A lot of problems encountered by many pharmaceutical enterprises are caused by the lack of enterprise cognition Second, we need to reshape our development strategy In the past, the traditional marketing model is no longer "magic medicine" in the face of the new situation of the industry The business model formed by relying on the transitional sales and non-standard operation has reached the point of unsustainability We must reshape the direction and goal, and re determine the measures to achieve the goal In addition, the production line and product line combination should be adjusted according to their own resources Innovation is the general trend of the industry Pharmaceutical enterprises should carry out innovation and transformation of production line and product line combination in accordance with their own strength and detailed planning But it's a long process, not one day, and pharmaceutical companies need to be prepared for a "long-term war".